BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38673835)

  • 1. The Recombinant Oncolytic Virus VV-GMCSF-Lact and Chemotherapy Drugs against Human Glioma.
    Vasileva N; Ageenko A; Byvakina A; Sen'kova A; Kochneva G; Mishinov S; Richter V; Kuligina E
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
    Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
    Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
    Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
    Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
    Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma.
    Vasileva N; Ageenko A; Dmitrieva M; Nushtaeva A; Mishinov S; Kochneva G; Richter V; Kuligina E
    Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.
    Dymova MA; Malysheva DO; Popova VK; Dmitrienko EV; Endutkin AV; Drokov DV; Mukhanov VS; Byvakina AA; Kochneva GV; Artyushenko PV; Shchugoreva IA; Rogova AV; Tomilin FN; Kichkailo AS; Richter VA; Kuligina EV
    Molecules; 2024 Feb; 29(4):. PubMed ID: 38398600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.
    Vasileva NS; Ageenko AB; Richter VA; Kuligina EV
    Acta Naturae; 2022; 14(2):62-70. PubMed ID: 35923561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells.
    Wang C; Li Q; Xiao B; Fang H; Huang B; Huang F; Wang Y
    J Clin Lab Anal; 2021 Mar; 35(3):e23677. PubMed ID: 33274495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
    Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts.
    Advani SJ; Buckel L; Chen NG; Scanderbeg DJ; Geissinger U; Zhang Q; Yu YA; Aguilar RJ; Mundt AJ; Szalay AA
    Clin Cancer Res; 2012 May; 18(9):2579-90. PubMed ID: 22379115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
    Inoue T; Byrne T; Inoue M; Tait ME; Wall P; Wang A; Dermyer MR; Laklai H; Binder JJ; Lees C; Hollingsworth R; Maruri-Avidal L; Kirn DH; McDonald DM
    Mol Cancer Ther; 2021 Aug; 20(8):1481-1494. PubMed ID: 34045231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
    Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
    Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of vaccinia virus in glioma model.
    Timiryasova TM; Li J; Chen B; Chong D; Langridge WH; Gridley DS; Fodor I
    Oncol Res; 1999; 11(3):133-44. PubMed ID: 10527073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.
    de Vries CR; Monken CE; Lattime EC
    Cancer Gene Ther; 2015 Apr; 22(3):154-62. PubMed ID: 25633483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GMCSF-armed vaccinia virus induces an antitumor immune response.
    Parviainen S; Ahonen M; Diaconu I; Kipar A; Siurala M; Vähä-Koskela M; Kanerva A; Cerullo V; Hemminki A
    Int J Cancer; 2015 Mar; 136(5):1065-72. PubMed ID: 25042001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.